Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.

Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia (2009) 1.77

Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol (2010) 0.94

Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol (2015) 0.78

Alteration in endoglin-related angiogenesis in refractory cytopenia with multilineage dysplasia. PLoS One (2013) 0.76

Blood vessels everywhere, but so few cells to fill them. Leuk Lymphoma (2006) 0.75

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44

Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80

Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med (2015) 3.90

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol (2011) 2.29

Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26

Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood (2011) 2.07

Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood (2008) 2.04

Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol (2011) 2.02

Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol (2010) 1.98

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88

Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood (2009) 1.84

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood (2010) 1.83

Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res (2011) 1.82

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood (2004) 1.81

Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res (2004) 1.71

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67

Mastocytosis: state of the art. Pathobiology (2007) 1.64

Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63

The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol (2004) 1.63

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood (2002) 1.62

Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol (2002) 1.62

Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma (2005) 1.61

Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol (2002) 1.54

Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol (2003) 1.54

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood (2005) 1.53

Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst (2011) 1.52

Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood (2006) 1.50

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget (2012) 1.50

A mimic of sarcoidosis. Lancet (2007) 1.49

Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol (2002) 1.47

Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res (2008) 1.46

High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res (2005) 1.44

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol (2010) 1.44

Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma (2006) 1.41

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood (2012) 1.40

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood (2011) 1.40

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res (2003) 1.39

Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leuk Lymphoma (2006) 1.39

[Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]. Wien Klin Wochenschr (2002) 1.38

A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood (2012) 1.36

The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res (2002) 1.35

Comprehensive mutational profiling in advanced systemic mastocytosis. Blood (2013) 1.35

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica (2010) 1.27

Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. J Immunol (2011) 1.26

Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol (2010) 1.25

Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res (2008) 1.25

Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol (2004) 1.24

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol (2014) 1.22

Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res (2005) 1.21

Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome. Int Arch Allergy Immunol (2006) 1.21

Masked polycythemia vera (mPV): results of an international study. Am J Hematol (2013) 1.19

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant (2008) 1.19

Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res (2004) 1.18

Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol (2002) 1.17

Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. Leuk Lymphoma (2006) 1.16